A biotech with a newly approved drug, a potentially cheap banking giant, and a possibly overvalued clinical-stage biotech with a promising rare-disease drug are this week’s must-watch stocks.
A biotech with a newly approved drug, a potentially cheap banking giant, and a possibly overvalued clinical-stage biotech with a promising rare-disease drug are this week’s must-watch stocks.